Shearwood McClelland, Director of Spine Oncology at University Hospitals’ Department of Radiation Oncology, shared a post by Justin Keister, Senior Medical Physicist at the Aurora Cancer Center in Kenosha, Aurora Health Care on X, adding:
“Any discussion of OS in GBM without mentioning Optune is not intellectually honest. Only Temodar and Optune (TumorTreatingFields TTF) have Level 1 evidence-supported OS benefit for GBM in the last century. TTF for GBM should be offered to all patients.”
Quoting Justin Keister’s post:
“The Stupp trial added 2.5 months mOS and established Temodar as the standard of care in GBM. Liau trial demonstrated that DCVAX adds ~4 months to mOS and doubles 5 year survival in new and recurrent GBM. Stuck in regulatory review for 2.5 years. ”
Title: Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
Authors: Roger Stupp, Sophie Taillibert, Andrew Kanner, William Read, David Steinberg, Benoit Lhermitte, Steven Toms, Ahmed Idbaih, Manmeet S. Ahluwalia, Karen Fink, Francesco Di Meco, Frank Lieberman, Jay-Jiguang Zhu, Giuseppe Stragliotto, David Tran, Steven Brem, Andreas Hottinger, Eilon D. Kirson, Gitit Lavy-Shahaf, Uri Weinberg, Chae-Yong Kim, Sun-Ha Paek, Garth Nicholas, Jordi Bruna, Hal Hirte, Michael Weller, Yoram Palti, Monika E. Hegi, Zvi Ram
Other articles featuring Shearwood McClelland on OncoDaily.